Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRO-First: Spironolactone in Low-Renin Hypertension
NCT07687160Phase 4Not yet recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jan 2027
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of spironolactone in hypertension (HTN) (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Recruitment Rate of Randomized Participants per Month at 12 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
spironolactone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07687160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07687160.